Upcoming conference attendance
Arecor Therapeutics plc announced its attendance at two major industry conferences: the American Diabetes Association (ADA) Scientific Sessions from June 5-8, 2026, in New Orleans, and the BIO International Convention from June 22-25, 2026, in San Diego. The company will showcase its lead clinical-stage product, AT278, an ultra-concentrated, ultra-rapid acting insulin designed for advanced automated insulin delivery systems. These events provide opportunities for Arecor's leadership and business development team to engage with key opinion leaders, researchers, investors, and potential partners, aiming to advance its pipeline and collaborations.
Select text to share a quote on X · sign in to keep highlights & notes in your AREC notes
Cambridge, UK, 18 May 2026: Arecor Therapeutics plc (AIM: AREC), a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases, will be attending the American Diabetes Association (ADA) 2026 Scientific Sessions and the BIO International Convention in San Diego.
American Diabetes Association (ADA) 2026 Scientific Sessions - 5-8 June 2026, New Orleans
Arecor's CEO, Dr Sarah Howell, and CSO, Dr Jan Jezek, will be attending ADA alongside over 12,000 leaders in the diabetes field, to meet with KOLs, researchers and investors. ADA is the largest meeting in the field of diabetes care, providing a platform for the latest advancements in technology and innovative treatments, including Arecor's lead clinical stage product, AT278. AT278 is the only ultra-concentrated, ultra-rapid acting insulin designed to accelerate the advancement of the next generation of Automated Insulin Delivery Systems.
BIO International Convention - 22-25 June 2026, San Diego
Jalini Gugagayanan, Business Development Manager at Arecor, will be attending the BIO International Convention, to meet potential partners and industry contacts at the largest and most comprehensive event for biotechnology, with over 20,000 industry leaders from around the world in attendance.
For attendees at either conference interested in meeting the Arecor team, please email BD@arecor.com.
About AT278
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.